The FDA approved certolizumab pegol (Cimzia, UCB Pharma) injection for treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. This is the first time the FDA has approved a treatment for this form of inflammatory arthritis.
“Today’s approval of Cimzia fulfills an unmet need for patients suffering from non-radiographic axial spondyloarthritis as there has been no FDA-approved treatments until now,” said Nikolay